Safety profile of the adjuvanted recombinant zoster vaccine : Pooled analysis of two large randomised phase 3 trials by López-Fauqued, Marta et al.
Vaccine 37 (2019) 2482–2493Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vaccineSafety profile of the adjuvanted recombinant zoster vaccine: Pooled
analysis of two large randomised phase 3 trialsqhttps://doi.org/10.1016/j.vaccine.2019.03.043
0264-410X/ 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Abbreviations: HZ, herpes zoster; RZV, adjuvanted recombinant zoster vaccine; VZV, varicella-zoster virus; gE, VZV glycoprotein E; AE, adverse event; SAE, se
pIMD, potential immune-mediated disease; D, day; M, month; Y, year; YOA, years of age; ZOE-50/70, the pivotal RZV efficacy trials in adults 50/70 YOA; MedDRA
dictionary for regulatory activities; SOC, system organ class; PT, preferred term; CI, confidence interval; RR, relative risk; AML, acute myeloid leukemia.
q Previous presentation: Part of these data have been presented at the Vaccines and Related Biological Products Advisory Committee Meeting, 13 September 201
Spring, MD, and at IDWeek, 04-08 October 2017, San Diego, CA (USA). Trademark statement: Shingrix is a trademark of the GSK group of companies.Marta López-Fauqued a,1, Laura Campora a,1,⇑, Frédérique Delannois a, Mohamed El Idrissi b, Lidia
Oostvogels a,2, Ferdinandus J. De Looze c, Javier Diez-Domingo d, Thomas C. Heineman e,3, Himal Lal e,4,
Janet E. McElhaney f, Shelly A. McNeil g, Wilfred Yeo h, Fernanda Tavares-Da-Silva a, for the ZOE-50/70
Study Group Anitta Ahonen i, Thiago Junquera Avelino-Silva j, Jose Fernando Barba-Gomez k, Johan
Berglund l, Carlos Brotons Cuixart m, Covadonga Caso n, Roman Chlibek o, Won Suk Choi p, Anthony L.
Cunninghamq, Maria Guiseppina Desole r, Peter Eizenberg s, Meral Esen t, Emmanuelle Espié u, Pierre
Gervais v, Wayne Ghesquiere w, Olivier Godeaux x, Iris Gorfinkel y, David Shu Cheong Hui z, Shinn-Jang
Hwang aa, Tiina Korhonen ab, Martina Kovac ac, Edouard Ledent ad, Edward Leung ae, Myron J. Levin af, Silvia
Narejos Perez ag, Jose Luiz Neto ah, Karlis Pauksens ai, Airi Poder aj, Maria Luisa Rodriguez de la Pinta ak, Lars
Rombo al, Tino F. Schwarz am, Jan Smetana an, Tommaso Staniscia ao, Juan Carlos Tinoco ap, Azhar Toma aq,
Ilse Vastiau ar, Timo Vesikari as, Antonio Volpi at, Daisuke Watanabe au, Lily Yin Weckx av, Toufik Zahaf aw
aGSK, Wavre, Belgium
bGSK, Rixensart, Belgium
cAusTrials Pty Ltd, Sherwood and School of Medicine, University of Queensland, Brisbane, Queensland, Australia
dVaccine Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica, Valencia, Spain
eGSK, King of Prussia, PA, USA
fHealth Sciences North Research Institute, Sudbury, Ontario, Canada
gCanadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia, Canada
h School of Medicine, University of Wollongong, Wollongong, Australia
iUniversity of Tampere, Järvenpää Vaccine Clinic, Finland
jUniversity of São Paulo Medical School, Brazil
k Instituto Dermatológico de Jalisco, Mexico
lBlekinge Institute of Technology, Sweden
m EAP Sardenya, Spain
nHospital Clínico San Carlos, Spain
oUniversity of Defence, Faculty of Military Health Sciences, Czech Republic
pKorea University College of Medicine, Republic of Korea
qWestmead Institute for Medical Research, University of Sydney, Australia
r Servizio di Igiene Pubblica, Italy
sDoctors of Ivanhoe, Australia
t Institut für Tropenmedizin, University Clinic of Tübingen, Germany
uGSK, Belgium
vQ&T Research Sherbrooke, Canada
wUniversity of British Columbia, Canada
xGSK, Belgium, during the conduct of the ZOE-50/70 trials, Belgium
yYork University, Canada
z Prince of Wales Hospital, Hong Kong
aa Taipei Veterans General Hospital and National Yang Ming University School of Medicine, Taiwan
abVaccine Research Centre, University of Tampere Medical School, Tampere, Finland
acGSK, USA
adGSK, Belgium
aeHong Kong Association of Gerontology, Hong Kong
afUniversity of Colorado Anschutz Medical Campus, USA
agCAP Centelles, Spain
ah Instituto A. Z. de Pesquisa e Ensino, Brazilrious AE;
, medical
7, Silver
M. López-Fauqued et al. / Vaccine 37 (2019) 2482–2493 2483aiUppsala University Hospital, Sweden
ajKliiniliste Uuringute Keskus, Estonia
akHospital Puerta de Hierro, Spain
alUppsala University, Sweden
am Standort Juliusspital, Germany
anUniversity of Defence, Faculty of Military Health Sciences, Czech Republic
aoUniversity G. d’Annunzio of Chieti-Pescara, Italy
apHospital General de Durango, Mexico
aqManna Research, Canada
arGSK, Belgium
asUniversity of Tampere, Finland
atA.O. Univesitaria Policlinico Tor Vergata, Italy
auKobe University Graduate School of Medicine, Japan
av Federal University of Sao Paulo, Brazil
awGSK, Belgiuma r t i c l e i n f o
Article history:
Received 15 November 2018
Received in revised form 14 March 2019
Accepted 20 March 2019
Available online 29 March 2019
Keywords:
Varicella-zoster virus
Vaccine
Safety
Reactogenicity⇑ Corresponding author at: GSK, Avenue Fleming 2
E-mail addresses:marta.x.lopez-fauqed@gsk.com (
s.elidrissi@gsk.com (M. El Idrissi), cornelia.oostvog
Oostvogels), cornelia.oostvogels@orange.fr (F.J. Oostv
gmail.com (J. Diez-Domingo), tch3768@gmail.com (T
McNeil), wilf@uow.edu.au (W. Yeo), fernanda.tavares
1 Both authors contributed equally to the manuscrip
2 Current affiliation: CureVac AG, Tübingen, German
3 Current affiliation: Halozyme Therapeutics, San Di
4 Current affiliation: Pfizer Vaccine Inc, Collegeville,a b s t r a c t
Background: The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that
the adjuvanted recombinant zoster vaccine (RZV) was 90% efficacious in preventing herpes zoster in
adults. Here we present a comprehensive overview of the safety data from these studies.
Methods: Adults aged 50 (ZOE-50) and 70 (ZOE-70) years were randomly vaccinated with RZV or pla-
cebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants
receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were col-
lected for 7 and 30 days after each vaccination, respectively. Serious AEs (SAEs) were collected from
the first vaccination until 12 months post-last dose. Fatal AEs, vaccination-related SAEs, and potential
immune-mediated diseases (pIMDs) were collected during the entire study period.
Results: Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recip-
ients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site
and solicited systemic reactions that were generally seen in the first week post-vaccination. The occur-
rence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs
(RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of
pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symp-
toms, the safety results were comparable between the RZV and Placebo groups irrespective of participant
age, gender, or race.
Conclusions: No safety concerns arose, supporting the favorable benefit-risk profile of RZV.
 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction the risk of HZ by over 90% in all age groups among adults 50YOAHerpes zoster (HZ) results from reactivation of latent varicella-
zoster virus (VZV) in the dorsal root ganglia, usually years after pri-
mary VZV infection. HZ is typically characterized by a unilateral
dermatomal vesicular rash, generally accompanied by pain. Its
most common complication is postherpetic neuralgia, a chronic
pain that can persist for months or years after the rash has resolved
[1]. HZ incidence increases substantially with age, from 3 to 5 cases
per 1000 person-years in the general population of all ages [2], to
4–8 cases per 1000 person-years in adults 50 years of age (YOA)
and 8–12 cases per 1000 person-years for those 80 YOA [2,3].
An adjuvanted recombinant zoster vaccine, RZV (Shingrix, GSK),
consisting of a truncated form of VZV glycoprotein E (gE) and the
AS01B adjuvant system, is currently licensed in different regions
worldwide for the prevention of HZ in adults 50 YOA. Two pivotal
phase 3 efficacy trials (ZOE-50/70) demonstrated that RZV reduces0, 1300 Wavre, Belgium.
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Pennsylvania, USA.[4,5]. Although the vaccine induces transient local and systemic
reactions, no safety concerns were identified during these clinical
trials. In both studies, serious adverse events (SAEs) and potential
immune-mediated diseases (pIMDs) were balanced between par-
ticipants in the RZV and Placebo groups [4,5].
The similar enrollment criteria, study procedures, and safety
follow-up period for the ZOE-50/70 trials allowed us to pool study
data. We present here a comprehensive analysis of the safety data
from pooled ZOE 50/70 studies.2. Methods
2.1. Study design and participants
ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229)were phase
3, randomized, placebo-controlled, observer-blinded clinical trialsa@gsk.com (L. Campora), frederique.x.delannois@gsk.com (F. Delannois), mohamed.
rnelia.oostvogels@orange.fr (F.J. Oostvogels), cornelia.oostvogels@orange.fr (F.J.
e.fr (F.J. Oostvogels), f.delooze@trialworks.com.au (F.J. De Looze), jdiezdomingo@
m (H. Lal), jmcelhaney@hsnri.ca (J.E. McElhaney), Shelly.McNeil@nshealth.ca (S.A.
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North and South America, Asia and Australia. Adults aged  50 YOA
(ZOE-50) or  70 YOA (ZOE-70) were randomized and vaccinated
with RZV or placebo (Supplementary Fig. 1). A full list of eligibility
criteria was previously presented [4,5], and is provided here in the
Supplementary Material. The two studies were conducted in an
identical manner, and adults 70 YOA were randomly enrolled to
participate in either the ZOE-50 or ZOE-70 study. Additional study
design details are presented in the primary publications [4,5]. The
clinical study reports are available at http://www.gsk-clinical-
studyregister.com (IDs 110390 and 113077). Anonymized individ-
ual participant data and study documents can be requested for
further research from www.clinicalstudydatarequest.com.
2.2. Study vaccines
RZV contains 50 lg of gE antigen and the GSK proprietary AS01B
Adjuvant System (containing 50 lg of 3-O-desacyl-40-monopho
sphoryl lipid A, 50 lg of Quillaja saponaria Molina, fraction 21
[licensed by GSK from Antigenics LLC, a wholly owned subsidiary
of Agenus Inc., a Delaware, USA corporation] and liposome).
Placebo consisted of 0.5 mL 150 mM NaCl solution.
2.3. Collection of safety data
Solicited adverse events (AEs) were collected for 7 days (D) after
each vaccination (D0-D6) in the reactogenicity sub-cohort, consist-
ing of participants who completed diary cards; severe AEs are
described in the Supplementary Material. Unsolicited AEs were
collected for 30D after each vaccination and graded on a scale from
1 (mild: not interfering with everyday activities) to 3 (severe: sig-
nificant at rest and preventing normal everyday activities). Unso-
licited AEs comprised both SAEs and non-serious AEs, including
all local and systemic reactions reported by participants who were
not part of the reactogenicity sub-cohort. Unsolicited AEs with
medically attended visits (defined as hospitalizations, emergency
room visits, or visits to or from medical personnel), other than rou-
tine health care visits, were recorded from first vaccine dose up to
6 months (M) post-last vaccination. SAEs were collected from the
first vaccine dose up to 1 year (Y) post-last vaccination. Fatal AEs,
SAEs considered causally related to study vaccination by the inves-
tigators, and pIMDs (new onset and possible exacerbations) were
collected during the entire study period. SAEs were defined accord-
ing to standard reporting guidelines [6]. AEs were coded by Medi-
cal Dictionary for Regulatory Activities (MedDRA) dictionary both
per System Organ Class (SOC) and Preferred Term (PT) [7]. Local
AEs were considered related to study vaccination. Relatedness of
other AEs was determined based on study investigators clinical
judgment, in a blinded manner. pIMDs were defined as a subset
of AEs that include autoimmune diseases and other inflammatory
and/or neurologic disorders of interest that may or may not have
an autoimmune etiology. AEs to be recorded as pIMDs were
pre-defined in the study protocol (Supplementary Table 1) and,
in addition, study investigators were instructed to use their medi-
cal judgment to determine whether other events could fall in this
category and to record them as pIMDs [8].
2.4. Statistical analysis
Safety analyses were performed on the pooled total vaccinated
cohort, consisting of participants who received at least one dose of
RZV/placebo. Analyses of unsolicited AEs, SAEs, and pIMDs were
descriptive and, for each of these, percentages of participants with
at least one event were calculated with their exact 95% Confidence
Intervals (CIs) both per SOC and PT. Analyses of SAEs, fatal AEs, and
pIMDs were performed up to 30D and 1Y post-last dose. In addi-tion, analyses of fatal AEs and pIMDs were also performed during
the entire study period. Exploratory analyses of unsolicited AEs
reported within the 30D post-vaccination period, SAEs and pIMDs
reported within 1Y post-last dose assessed the relative risks (RRs)
and frequencies of selected events of interest using MedDRA
queries. RRs and their 95% CIs were calculated by Exact Tests con-
ditional to the number of cases. Additional details are presented in
the Supplementary Material.3. Results
3.1. Study population
A total of 14,645 RZV and 14,660 placebo recipients were
included in the pooled analysis. The median follow-up duration
was 4.4Y. The mean age of the participants was 68.6Y; 58.2% of
those were female. Most (73.7%) participants were white/Cau-
casian. Demographic characteristics were comparable between
groups (Supplementary Table 2).
3.2. Reactogenicity
In line with previously reported reactogenicity results from the
ZOE-50/70 studies [4,5], RZV was more reactogenic than placebo in
the pooled reactogenicity sub-cohort. Pain was the most frequent
solicited local symptom reported after 68.1% (95% CI: 67.1–69.0)
of documented doses in the RZV group and after 6.9% (95% CI:
6.4–7.4) in the Placebo group. Grade 3 pain was reported after
3.8% (95% CI: 3.5–4.3) of documented doses in the RZV group and
after 0.2% (95% CI: 0.1–0.3) in the Placebo group. In the RZV group,
the most frequently reported solicited general symptoms were
myalgia and fatigue, reported after 32.9% (95% CI: 31.9–33.8) and
32.2% (95% CI: 31.3–33.2) of doses, respectively. Grade 3 fatigue
was reported after 3.0% (95% CI: 2.6–3.3) of documented doses in
the RZV group and after 0.5% (95% CI: 0.4–0.7) in the placebo group
(Supplementary Fig. 2). Local and general symptoms in the RZV
group were mostly mild to moderate in intensity and transient
(median duration was of 3 days or less for local and 2 days or less
for general symptoms, including grade 3 symptoms). Overall, there
were no differences in the proportions of RZV recipients reporting
any grade or grade 3 solicited local events between dose 1 and dose
2. All-grade solicited general symptoms tended to be more fre-
quent after dose 2 compared to dose 1.
3.3. Unsolicited adverse events
The percentage of participants reporting unsolicited AEs during
30D post-vaccination was greater for RZV than for placebo recipi-
ents (7393 [50.5%] versus 4689 [32.0%]; RR: 1.58 [95%CI:1.52–
1.64]; p < 0.0001). RZV recipients reported unsolicited AEs more
frequently, irrespective of age group, gender, or race (Table 1).
Unsolicited AEs more frequently reported by RZV recipients were
injection site and general symptoms that were reported as solicited
reactions in the reactogenicity sub-cohort (Table 1). More RZV than
placebo recipients reported unsolicited AEs during the first week
(D0-D6) post-vaccination (5861 [40.0%] versus 2230 [15.2%]).
Unsolicited AEs were balanced between groups during the subse-
quent 23D (D7-D29) post-vaccination period (3,076 [21.0%] versus
3,280 [22.4%]) (Fig. 1).
Unsolicited AEs not categorized as solicited AEs in the reacto-
genicity sub-cohort, those occurring in >1% of RZV recipients and
more frequently than in placebo recipients were, by PT: injection
site pruritus, pain, injection site warmth, pain in extremity,
malaise, arthralgia, back pain, dizziness, upper respiratory tract
infection, and oropharyngeal pain (Table 1).
Table 1
Unsolicited Adverse Events reported within 30 days after vaccination (Pooled Total Vaccinated Cohort).
RZV (N = 14,645) Placebo (N = 14,660) Relative Risk
95% CI 95% CI 95% CI
n % LL UL n % LL UL RR LL UL
Unsolicited adverse events (any grade) 7393 50.5 49.67 51.29 4689 32 31.23 32.75 1.58 1.52 1.64 ***
Grade 3 1094 7.5 7.0 7.9 563 3.8 3.5 4.2
Considered related 5052 34.5 33.7 35.3 968 6.6 6.2 7.0
Age
50–69 YOA; N = 5887 (RZV), 5887 (Placebo) 3027 51.4 50.1 52.7 1957 33.2 32.0 34.5
70 YOA; N = 8758 (RZV), 8773 (Placebo) 4366 49.9 48.8 50.9 2732 31.1 30.2 32.1
Sex
Female; N = 8498 (RZV), 8547 (Placebo) 4578 53.9 2932 34.3
Male; N = 6147 (RZV), 6113 (Placebo) 2815 45.8 1757 28.7
Race
White; N = 10,878 (RZV), 10,883 (Placebo) 5360 49.3 3382 31.1
Black; N = 219 (RZV), 196 (Placebo) 77 35.2 50 25.5
Asian; N = 2682 (RZV), 2688 (Placebo) 1527 56.9 934 34.7
Other; N = 866 (RZV), 893 (Placebo) 429 49.5 323 36.2
Reported in > 1% of RZV recipients
General disorders and administration site conditions
Injection site painy
Any grade 3365 22.98 22.30 23.67 252 1.72 1.51 1.94 13.37 11.76 15.25 ***
Grade 3 212 1.4 1.3 1.7 5 0.0 0.0 0.1
Considered related 3362 23.0 22.3 23.6 252 1.7 1.5 1.9
Injection site erythemay
Any grade 1357 9.27 8.80 9.75 37 0.25 0.18 0.35 36.71 26.50 52.37 ***
Grade 3 58 0.4 0.3 0.5 0.0 0.0 0.0 0.0
Considered related 1356 9.3 8.8 9.7 37 0.3 0.2 0.3
Pyrexiay
Any grade 1037 7.08 6.67 7.51 76 0.52 0.41 0.65 13.66 10.81 17.48 ***
Grade 3 138 0.9 0.8 1.1 10 0.1 0.0 0.1
Considered related 979 6.7 6.3 7.1 31 0.2 0.1 0.3
Injection site swellingy
Any grade 1014 6.92 6.52 7.35 22 0.15 0.09 0.23 46.14 30.30 73.96 ***
Grade 3 42 0.3 0.2 0.4 0.0 0.0 0.0 0.0
Considered related 1014 6.9 6.5 7.3 22 0.2 0.1 0.2
Fatiguey
Any grade 522 3.56 3.27 3.88 140 0.95 0.80 1.13 3.73 3.09 4.53 ***
Grade 3 62 0.4 0.3 0.5 7 0.0 0.0 0.1
Considered related 459 3.1 2.9 3.4 83 0.6 0.5 0.7
Chillsy
Any grade 516 3.52 3.23 3.83 35 0.24 0.17 0.33 14.76 10.47 21.42 ***
Grade 3 87 0.6 0.5 0.7 2 0.0 0.0 0.0
Considered related 498 3.4 3.1 3.7 25 0.2 0.1 0.3
Injection site pruritus
Any grade 317 2.16 1.94 2.41 35 0.24 0.17 0.33 9.07 6.38 13.25 ***
Grade 3 7 0.0 0.0 0.1 1 0.0 0.0 0.0
Considered related 313 2.1 1.9 2.4 35 0.2 0.2 0.3
Malaise
Any grade 254 1.73 1.53 1.96 43 0.29 0.21 0.39 5.91 4.27 8.37 ***
Grade 3 25 0.2 0.1 0.3 3 0.0 0.0 0.1
Considered related 237 1.6 1.4 1.8 24 0.2 0.1 0.2
Pain
Any grade 204 1.39 1.21 1.60 34 0.23 0.16 0.32 6.01 4.16 8.91 ***
Grade 3 30 0.2 0.1 0.3 3 0.0 0.0 0.1
Considered related 170 1.2 1.0 1.3 9 0.1 0.0 0.1
Injection site warmth
Any grade 149 1.02 0.86 1.19 5 0.03 0.01 0.08 29.83 12.50 93.22 ***
Grade 3 4 0.0 0.0 0.1 0 0.0 0.0 0.0
Considered related 149 1.0 0.9 1.2 5 0.0 0.0 0.1
Nervous system disorders
Headachey
Any grade 954 6.51 6.12 6.93 445 3.04 2.76 3.33 2.15 1.92 2.41 ***
Grade 3 99 0.7 0.5 0.8 27 0.2 0.1 0.3
Considered related 729 5.0 4.6 5.3 167 1.1 1.0 1.3
Dizziness
Any grade 182 1.24 1.07 1.44 113 0.77 0.64 0.93 1.61 1.27 2.06 ***
Grade 3 22 0.2 0.1 0.2 13 0.1 0.0 0.2
Considered related 110 0.8 0.6 0.9 47 0.3 0.2 0.4
(continued on next page)
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Table 1 (continued)
RZV (N = 14,645) Placebo (N = 14,660) Relative Risk
95% CI 95% CI 95% CI
n % LL UL n % LL UL RR LL UL
Infections and infestations
Nasopharyngitis
Any grade 492 3.36 3.07 3.66 538 3.67 3.37 3.99 0.92 0.81 1.04
Grade 3 32 0.2 0.1 0.3 25 0.2 0.1 0.3
Considered related 75 0.5 0.4 0.6 36 0.2 0.2 0.3
Upper respiratory tract infection
Any grade 231 1.58 1.38 1.79 182 1.24 1.07 1.43 1.27 1.04 1.55 *
Grade 3 18 0.1 0.1 0.2 16 0.1 0.1 0.2
Considered related 16 0.1 0.1 0.2 11 0.1 0.0 0.1
Musculoskeletal and connective tissue disorders
Myalgiay
Any grade 478 3.26 2.98 3.56 105 0.72 0.59 0.87 4.56 3.68 5.68 ***
Grade 3 63 0.4 0.3 0.6 8 0.1 0.0 0.1
Considered related 431 2.9 2.7 3.2 43 0.3 0.2 0.4
Arthralgia
Any grade 252 1.72 1.52 1.94 171 1.17 1.00 1.35 1.48 1.21 1.80 ***
Grade 3 27 0.2 0.1 0.3 15 0.1 0.1 0.2
Considered related 131 0.9 0.7 1.1 25 0.2 0.1 0.3
Pain in extremity
Any grade 155 1.06 0.90 1.24 107 0.73 0.60 0.88 1.45 1.13 1.87 *
Grade 3 14 0.1 0.1 0.2 9 0.1 0.0 0.1
Considered related 50 0.3 0.3 0.4 10 0.1 0.0 0.1
Back pain
Any grade 211 1.44 1.25 1.65 186 1.27 1.09 1.46 1.14 0.93 1.39
Grade 3 27 0.2 0.1 0.3 22 0.2 0.1 0.2
Considered related 45 0.3 0.2 0.4 18 0.1 0.1 0.2
Respiratory, thoracic and mediastinal disorders
Cough
Any grade 209 1.43 1.24 1.63 210 1.43 1.25 1.64 1.00 0.82 1.21
Grade 3 14 0.1 0.1 0.2 16 0.1 0.1 0.2
Considered related 19 0.1 0.1 0.2 12 0.1 0.0 0.1
Oropharyngeal pain
Any grade 165 1.13 0.96 1.31 154 1.05 0.89 1.23 1.07 0.86 1.34
Grade 3 6 0.0 0.0 0.1 8 0.1 0.0 0.1
Considered related 37 0.3 0.2 0.3 20 0.1 0.1 0.2
Gastrointestinal disorders
Nauseay
Any grade 197 1.35 1.16 1.55 69 0.47 0.37 0.60 2.86 2.16 3.82 ***
Grade 3 26 0.2 0.1 0.3 6 0.0 0.0 0.1
Considered related 167 1.1 1.0 1.3 32 0.2 0.1 0.3
Adverse events are presented by System Organ Class and Preferred Term, in order of most frequently reported in RZV recipients. Only adverse events reported by > 1% of RZV
recipients are presented here. Significance testing on relative risks was performed on all-grade events, irrespective of relatedness.
RZV = participants receiving the adjuvanted Recombinant Zoster Vaccine; Placebo = participants receiving placebo; N = number of participants in the pooled total vaccinated
cohort; n/% = number/percentage of participants reporting an event in each category; YOA = years of age; 95% CI = 95% Confidence Interval; RR = Relative Risk; LL/UL = Lower
Limit/Upper Limit of 95% Confidence Interval. y denotes adverse events classified as solicited adverse events in the reactogenicity sub-cohort; Stars indicate significance of
difference as expressed by the relative risk: * = p  0.05; ** = p  0.01; *** = p  0.001.
2486 M. López-Fauqued et al. / Vaccine 37 (2019) 2482–2493The frequency of grade 3 unsolicited AEs was also higher in RZV
than in placebo recipients within D0-D6 post-vaccination (Fig. 1)
due to PTs covering the local and general symptoms reported by
participants who were not part of the reactogenicity sub-cohort.
The most frequent grade 3 unsolicited AEs in the RZV group were
injection site pain, pyrexia, and headache. Injection site pain was
the only PT under which grade 3 unsolicited AEs were reported
by >1% of RZV recipients and had a higher frequency as compared
to the Placebo group (Table 1).
Unsolicited AEs with medically attended visits were reported by
2751 (18.8%) RZV and 2774 (18.9%) placebo recipients during the
30D post-vaccination, and by 5834 (39.8) RZV and 5983 (40.8%)
placebo recipients within 6 M post-last dose. The incidence of
unsolicited AEs with medically attended visits was similarbetween the RZV and Placebo groups in both males and females,
in participants of any race, and in both age cohorts within the same
period; incidences were also comparable between the age cohorts
(Supplementary Table 3).
3.4. Serious adverse events
Overall, the occurrence of SAEs was similar in both groups for
all time periods analyzed. Within 30D post-last dose, 342 (2.3%)
RZV and 327 (2.2%) placebo recipients reported at least one SAE.
Within 1Y post-last dose, SAEs were reported by 1482 (10.1%)
and 1525 (10.4%) participants in the RZV and Placebo groups,
respectively (RR = 0.97 [95%CI:0.91–1.05]; p = 0.46). During the
entire study period, SAEs considered causally related to vaccina-
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Fig. 1. Unsolicited Adverse Events reported in the 30 days after vaccination – days 0–6 and 7–29 post-vaccination (Pooled Total Vaccinated Cohort). RZV = participants
receiving the adjuvanted Recombinant Zoster Vaccine; Placebo = participants receiving placebo. Bars present percentage of study population experiencing any unsolicited
event, error bars present 95% Confidence Intervals.
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each group (Table 2, Supplementary Table 4).
Within 1Y post-last dose, SAE incidence was similar between
the RZV and Placebo groups in both age cohorts, in both males
and females, and in participants of any race (Table 2). In both study
groups, the most frequently reported SAEs by SOC were: infections
and infestations (RZV: 299 [2.04%], Placebo: 302 [2.06%]), cardiac
disorders (RZV: 290 [1.98%], Placebo: 318 [2.17%]), and neoplasms
benign, malignant and unspecified (RZV: 226 [1.54%], Placebo: 225
[1.53%], Fig. 2). By PT, the most frequently reported SAEs in both
groups were pneumonia (RZV: 83 [0.57%], Placebo: 66 [0.45%])
and atrial fibrillation (RZV: 55 [0.38%], Placebo: 58 [0.40%],
Table 2).
Statistically significant imbalances based on the nominal unad-
justed p-value (p < 0.05) between RZV and placebo recipients were
found for four individual SAEs by PT (Table 2). Six (<0.05%) RZV
recipients reported SAEs under the supraventricular tachycardia
PT versus no participants in the Placebo arm. By grouping
supraventricular tachycardia with other PTs that are pathophysio-
logically similar to or synonymous with supraventricular tachycar-
dia (i.e. arrhythmia supraventricular, atrial fibrillation, atrial
flutter, atrial tachycardia, cardiac flutter, tachyarrhythmia, and
tachycardia paroxysmal), the data showed no imbalance between
RZV and placebo recipients (69 [0.47%] versus 66 [0.45%];
RR = 1.05 [95%CI:0.74–1.49]; p = 0.86). PTs under which SAEs were
reported more frequently in placebo than in RZV recipients, were
aortic stenosis (0 [0.00%] versus 10 [0.07%]; RR = 0.00 [95%
CI:0.00–0.35]; p = 0.0020), cardio-respiratory arrest (0 [0.00%] ver-
sus 6 [0.04%]; RR = 0.00 [95%CI:0.00–0.65]; p = 0.0313), and retinal
detachment (1 [0.01%] versus 8 [0.05%]; RR = 0.13 [95%CI:0.00–
0.93]; p = 0.0392).3.5. Fatal adverse events
Overall, the percentage of participants reporting fatal AEs was
similar between RZV and placebo recipients during all time periodsanalyzed. Within 30D post-last dose, 17 (0.1%) RZV and 21 (0.1%)
placebo recipients reported fatal AEs. Within 1Y post-last dose,
fatal AEs were reported by 153 (1.1%) and 168 (1.1%) participants
in the RZV and Placebo groups, respectively (Table 3).
During the entire study period, fatal AEs were reported by 634
(4.3%) participants in the RZV group and by 680 (4.6%) participants
in the Placebo group. The occurrence of fatal AEs was similar
between groups in both age cohorts, but higher in participants
70 YOA compared to those 50–69 YOA (Table 3). The most fre-
quently reported fatal AEs by SOC in each study group were neo-
plasms benign, malignant and unspecified (RZV: 182 [1.2%],
Placebo: 177 [1.2%]), followed by cardiac disorders (RZV: 174
[1.2%], Placebo: 193 [1.3%]), and infections and infestations (RZV:
103 [0.7%], Placebo: 107 [0.7%]). The most frequently reported fatal
AEs by PT were cardiac failure, pneumonia, myocardial infarction,
death (with no specified cause), and cardiac arrest (Table 3).
One fatal AE was assessed as possibly vaccine-related by the
investigator. A 90-year-old male study participant with a past
medical history of stable immune-mediated thrombocytopenia
for approximately 10Y prior to vaccination developed pancytope-
nia and was diagnosed, on the basis of a bone marrow biopsy, with
acute myeloid leukemia (AML) 75D after receiving the first RZV
dose. He was hospitalized and withdrawn from study treatment.
The study participant died 97D post-dose 1 due to neutropenic
sepsis.3.6. Potential immune-mediated diseases
Overall, the occurrence of pIMDs (new onset and possible exac-
erbations) was similar between RZV and placebo recipients during
all time periods analyzed. Up to 30D post-last dose, pIMDs were
reported by 30 (0.2%) participants in each group. pIMDs were
reported by 90 (0.6%) RZV and 105 (0.7%) placebo recipients up
to 1Y post-last dose, and by 179 (1.2%) RZV and 202 (1.4%) placebo
recipients during the entire study period. Up to 1Y post-last dose,
Table 2
Serious Adverse Events reported during the ZOE-50/70 clinical trials (Pooled Total Vaccinated Cohort).
RZV (N = 14,645) Placebo (N = 14,660) Relative Risk
95% CI 95% CI 95% CI
n % LL UL n % LL UL RR LL UL
Reported within 30 days post-last dose
Any event 342 2.3 2.1 2.6 327 2.2 2.0 2.5
Reported within 1 year post-last dose
Any event 1482 10.1 9.6 10.6 1525 10.4 9.9 10.9 0.97 0.91 1.05
Age
50–69 YOA; N = 5887 (RZV), 5887 (Placebo) 367 6.2 5.6 6.9 359 6.1 5.5 6.7
70 YOA; N = 8758 (RZV), 8773 (Placebo) 1115 12.7 12.0 13.4 1166 13.3 12.6 14.0
Sex
Female; N = 8498 (RZV), 8547 (Placebo) 748 8.8 763 8.9
Male; N = 6147 (RZV), 6113 (Placebo) 734 11.9 762 12.5
Race
White; N = 10,878 (RZV), 10,883 (Placebo) 1118 10.3 1149 10.6
Black; N = 219 (RZV), 196 (Placebo) 23 10.5 26 13.3
Asian; N = 2682 (RZV), 2688 (Placebo) 280 10.4 288 10.7
Other; N = 866 (RZV), 893 (Placebo) 61 7.0 62 6.9
Reported during the entire study period
Considered related 15 0.1 0.1 0.2 15 0.1 0.1 0.2
Reported in > 0.3% of RZV recipients
Cardiac disorders
Atrial Fibrillation 55 0.38 0.28 0.49 58 0.40 0.30 0.51 0.95 0.64 1.4
Infections and Infestations
Pneumonia 83 0.57 0.45 0.7 66 0.45 0.35 0.57 1.26 0.90 1.77
Statistically significant differences in occurrence between RZV and Placebo
Vascular Disorders
Aortic Stenosis** 0 0 0 0.03 10 0.07 0.03 0.13 0.00 0.00 0.35
Cardiac Disorders
Supraventricular Tachycardia* 6 0.04 0.02 0.09 0 0 0 0.03 INF 1.55 INF
Cardio-respiratory arrest* 0 0 0 0.03 6 0.04 0.02 0.09 0.00 0.00 0.65
Eye Disorders
Retinal detachment* 1 0.01 0 0.04 8 0.05 0.02 0.11 0.13 0.00 0.93
Serious adverse events are presented by System Organ Class and Preferred Term, in order of most frequently reported in RZV recipients. Only serious adverse events reported
by > 0.3% of RZV recipients are presented here. Significance testing on relative risks was performed irrespective of relatedness. Details on serious adverse events considered
related to vaccination by study investigators are provided in Supplementary Table 4.
RZV = participants receiving the adjuvanted Recombinant Zoster Vaccine; Placebo = participants receiving placebo; N = number of participants in the pooled total vaccinated
cohort; n/% = number/percentage of participants reporting an event in each category; YOA = years of age; 95% CI = 95% Confidence Interval; RR = Relative Risk; LL/UL = Lower
Limit/Upper Limit of 95% Confidence Interval; INF = estimation considered infinite.
Stars indicate significance of difference as expressed by the relative risk: * = p  0.05; ** = p  0.01.
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Fig. 2. Serious Adverse Events reported within 1 year post-last dose (Pooled Total Vaccinated Cohort). RZV = participants receiving the adjuvanted Recombinant Zoster
Vaccine; Placebo = participants receiving placebo; N = number of participants in the pooled total vaccinated cohort; MedDRA = Medical Dictionary for Regulatory Activities;
SOC = System Organ Class; SAE = Serious Adverse Event.
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Table 3
Adverse Events with fatal outcome reported during the ZOE-50/70 clinical trials (Pooled Total Vaccinated Cohort).
RZV (N = 14,645) Placebo (N = 14,660)
95% CI 95% CI
n % LL UL n % LL UL
Reported within 30 days post-last dose
Any event 17 0.1 0.1 0.2 21 0.1 0.1 0.2
Reported within 1 year post-last dose
Any event 153 1.0 0.9 1.2 168 1.1 1.0 1.3
Reported during the entire study period
Any event 634 4.3 4.0 4.7 680 4.6 4.3 5.0
Age
50–69 YOA; N = 5887 (RZV), 5887 (Placebo) 95 1.6 1.3 2.0 100 1.7 1.4 2.1
70 YOA; N = 8758 (RZV), 8773 (Placebo) 539 6.2 5.7 6.7 580 6.6 6.1 7.2
Reported in  0.1% of RZV recipients during the entire study period
Cardiac Disorders
Cardiac failure 42 0.3 0.2 0.4 53 0.4 0.3 0.5
Myocardial infarction 39 0.3 0.2 0.4 39 0.3 0.2 0.4
Cardiac arrest 29 0.2 0.1 0.3 23 0.2 0.1 0.2
Acute myocardial infarction 13 0.1 0.0 0.2 24 0.2 0.1 0.2
Cardiac failure congestive 11 0.1 0.0 0.1 15 0.1 0.1 0.2
Cardiogenic shock 9 0.1 0.0 0.1 2 0.0 0.0 0.0
Infections and infestations
Pneumonia 39 0.3 0.2 0.4 47 0.3 0.2 0.4
Sepsis 21 0.1 0.1 0.2 20 0.1 0.1 0.2
Septic shock 10 0.1 0.0 0.1 14 0.1 0.1 0.2
General disorders and administration site conditions
Death 28 0.2 0.1 0.3 44 0.3 0.2 0.4
Sudden death 18 0.1 0.1 0.2 11 0.1 0.0 0.1
Multi-organ failure 15 0.1 0.1 0.2 13 0.1 0.0 0.2
Neoplasms benign, malignant and unspecified
Lung neoplasm malignant 27 0.2 0.1 0.3 13 0.1 0.0 0.2
Pancreatic carcinoma 12 0.1 0.0 0.1 18 0.1 0.1 0.2
Lung cancer metastatic 8 0.1 0.0 0.1 5 0.0 0.0 0.1
Nervous system disorders
Cerebrovascular accident 19 0.1 0.1 0.2 23 0.2 0.1 0.2
Cerebral infarction 9 0.1 0.0 0.1 9 0.1 0.0 0.1
Respiratory, thoracic and mediastinal disorders
Respiratory failure 16 0.1 0.1 0.2 19 0.1 0.1 0.2
Chronic obstructive pulmonary disease 9 0.1 0.0 0.1 11 0.1 0.0 0.1
Pneumonia aspiration 8 0.1 0.0 0.1 6 0.0 0.0 0.1
Renal and urinary disorders
Acute kidney injury 14 0.1 0.1 0.2 8 0.1 0.0 0.1
Adverse events with fatal outcome are presented by System Organ Class and Preferred Term, in order of most frequently reported in RZV recipients. Only adverse events with
fatal outcome reported by  0.1% of RZV recipients are presented here.
RZV = participants receiving the adjuvanted Recombinant Zoster Vaccine; Placebo = participants receiving placebo; N = number of participants in the pooled total vaccinated
cohort; n/% = number/percentage of participants reporting an event in each category; YOA = years of age; 95% CI = 95% Confidence Interval; LL/UL = Lower Limit/Upper Limit
of 95% Confidence Interval.
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were reported by 15 (0.1%) participants in each group (Table 4).
Overall, occurrences of pIMDs during the entire study period
were similar between RZV and placebo recipients irrespective of
age cohort, gender, or race (Table 4). The most frequently reported
pIMDs by PT were polymyalgia rheumatica, rheumatoid arthritis,
psoriasis, and autoimmune thyroiditis (Table 4, Supplementary
Table 5).
The additional analysis of participants with pre-existing pIMDs
revealed that 983 (6.7%) RZV and 960 (6.5%) placebo recipients had
a pre-existing pIMD at enrollment (Table 5, Supplementary Fig. 3).
The most common pre-existing pIMDs at baseline by PT were pso-
riasis (RZV: 215 [21.9%], Placebo: 239 [24.9%]), spondyloarthropa-
thy (RZV: 109 [11.1%], Placebo: 89 [9.3%]), and rheumatoid
arthritis (RZV: 96 [9.8%], Placebo: 94 [9.8%]). Over 95% of partici-
pants with a pre-existing pIMD did not experience a possible exac-
erbation of a pre-existing pIMD nor an onset of a new pIMD during
the study. Among participants with pre-existing pIMDs, onset of
new pIMDs were reported by 16 (1.6%) RZV and 23 (2.4%) placebo
recipients, and possible exacerbation of pre-existing pIMD by 27
(2.8%) of participants in each group (Table 5).4. Discussion
Overall, the pooled safety data from ZOE-50/70 studies did not
reveal any safety concerns. A plain language summary contextual-
izing the results and potential clinical research relevance and
impact is displayed in the Focus on Patient Section (Supplementary
Fig. 4).
Unsolicited symptoms were more frequent in RZV recipients,
driven by local and systemic reactions reported during D0-D6
post-vaccination by participants who were not part of the reacto-
genicity sub-cohort [4,5]. Data published previously showed that
RZV induces transient local and systemic reactions, such as injec-
tion site pain and, to a lesser extent, fatigue and myalgia [4,5,9–
11]. In line with these findings, the pooled analysis presented here
shows a similar profile of transient local and systemic reactions to
the vaccine (including those of grade 3 intensity) occurring during
D0-D6 post-vaccination. No clinically significant imbalance in
other unsolicited AEs was observed.
The nature of the SAEs reported in the pooled ZOE-50/70 stud-
ies reflects those observed in the general older adult population
[12,13], and overall, no apparent differences were observed
Table 4
Potential Immune-Mediated Diseases reported during the ZOE-50/70 clinical trials (Pooled Total Vaccinated Cohort).
RZV (N = 14,645) Placebo (N = 14,660) Relative Risk
95% CI 95% CI 95% CI
n % LL UL n % LL UL RR LL UL
Reported within 30 days post-last dose
Any event 30 0.2 0.1 0.3 30 0.2 0.1 0.3
Reported within 1 year post-last dose
Any Event 90 0.6 0.5 0.8 105 0.7 0.6 0.9 0.86* 0.64 1.15
Considered related 15 0.1 0.1 0.2 15 0.1 0.1 0.2
Reported during the entire study period
Any event 179 1.2 1.1 1.4 202 1.4 1.2 1.6
Age
50–69 YOA; N = 5887 (RZV), 5887 (Placebo) 69 1.2 0.9 1.5 84 1.4 1.1 1.8
70 YOA; N = 8758 (RZV), 8773 (Placebo) 110 1.3 1.0 1.5 118 1.3 1.1 1.6
Sex
Female; N = 8498 (RZV), 8547 (Placebo) 115 1.4 128 1.5
Male; N = 6147 (RZV), 6113 (Placebo) 64 1.0 74 1.2
Race
White; N = 10,878 (RZV), 10,883 (Placebo) 153 1.4 171 1.6
Black; N = 219 (RZV), 196 (Placebo) 1 0.5 0 0
Asian; N = 2682 (RZV), 2688 (Placebo) 19 0.7 23 0.9
Other; N = 866 (RZV), 893 (Placebo) 6 0.7 8 0.9
Reported in  0.1% of RZV recipients
Musculoskeletal and connective tissue disorders
Polymyalgia rheumatica 32 0.2 0.1 0.3 29 0.2 0.1 0.3
Rheumatoid arthritis 20 0.1 0.1 0.2 26 0.2 0.1 0.3
Skin and subcutaneous tissue disorders
Psoriasis 15 0.1 0.1 0.2 18 0.1 0.1 0.2
Endocrine disorders
Autoimmune thyroiditis 13 0.1 0.0 0.2 10 0.1 0.0 0.1
Nervous system disorders
VIIth nerve paralysis 8 0.1 0.0 0.1 7 0.0 0.0 0.1
Potential immune-mediated diseases are presented by System Organ Class and Preferred Term, in order of most frequently reported in RZV recipients. Only diseases reported
by  0.1% of RZV recipients are presented. A full list of potential immune-mediated diseases reported during the clinical trials is presented in Supplementary Table 5.
Significance testing on relative risks was performed irrespective of relatedness. * p = 0.3195.
RZV = participants receiving the adjuvanted Recombinant Zoster Vaccine; Placebo = participants receiving placebo; N = number of participants in the pooled total vaccinated
cohort; n/% = number/percentage of participants reporting an event in each category; YOA = years of age; 95% CI = 95% Confidence Interval; RR = Relative Risk; LL/UL = Lower
Limit/Upper Limit of 95% Confidence Interval.
Table 5
Potential Immune-Mediated Diseases reported during the ZOE-50/70 clinical trials in participants with a pre-existing potential Immune-Mediated Disease at enrolment (Total
Vaccinated Cohort with pre-existing pIMD).
RZV (N = 983) Placebo (N = 960)
95% CI 95% CI
n % LL UL n % LL UL
No pre-existing pIMD exacerbation or new pIMD onset 940 95.6 912 95.0
Exacerbation of a pre-existing pIMD
Any Event 27 2.8 1.8 4.0 27 2.8 1.9 4.1
Blood and lymphatic system disorders
Immune thrombocytopenic purpura 2 0.2 0.0 0.7 1 0.1 0.0 0.6
Endocrine disorders
Basedow’s disease 2 0.2 0.0 0.7 0 0 0.0 0.4
Eye disorders
Uveitis 0 0 0.0 0.4 1 0.1 0.0 0.6
Gastrointestinal disorders
Colitis ulcerative 1 0.1 0.0 0.6 1 0.1 0.0 0.6
Metabolism and nutrition disorders
Type 1 diabetes mellitus 0 0 0.0 0.4 1 0.1 0.0 0.6
Musculoskeletal and connective tissue disorders
Crest syndrome 0 0 0.0 0.4 1 0.1 0.0 0.6
Polymyalgia rheumatica 2 0.2 0.0 0.7 3 0.3 0.1 0.9
Psoriatic arthropathy 0 0 0.0 0.4 1 0.1 0.0 0.6
Rheumatoid arthritis 3 0.3 0.1 0.9 5 0.5 0.2 1.2
Spondyloarthropathy 4 0.4 0.1 1.0 2 0.2 0.0 0.8
Nervous system disorders
VIIth nerve paralysis 1 0.1 0.0 0.6 0 0 0.0 0.4
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis 2 0.2 0.0 0.7 1 0.1 0.0 0.6
Skin and subcutaneous tissue disorders
Alopecia areata 0 0 0.0 0.4 1 0.1 0.0 0.6
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Table 5 (continued)
RZV (N = 983) Placebo (N = 960)
95% CI 95% CI
n % LL UL n % LL UL
Erythema nodosum 0 0 0.0 0.4 1 0.1 0.0 0.6
Pemphigus 0 0 0.0 0.4 1 0.1 0.0 0.6
Psoriasis 9 0.9 0.4 1.7 4 0.4 0.1 1.1
Vitiligo 0 0 0.0 0.4 1 0.1 0.0 0.6
Vascular disorders
Raynaud’s phenomenon 1 0.1 0.0 0.6 1 0.1 0.0 0.6
Temporal arteritis 0 0 0.0 0.4 1 0.1 0.0 0.6
New onset pIMD
Any event 16 1.6 0.9 2.6 23 2.4 1.5 3.6
Endocrine disorders
Autoimmune thyroiditis 0 0 0.0 0.4 1 0.1 0.0 0.6
Basedow’s disease 0 0 0.0 0.4 1 0.1 0.0 0.6
Gastrointestinal disorders
Autoimmune pancreatitis 1 0.1 0.0 0.6 0 0 0.0 0.4
Chronic gastritis 1 0.1 0.0 0.6 0 0 0.0 0.4
Coeliac disease 0 0 0.0 0.4 1 0.1 0.0 0.6
Crohn’s disease 1 0.1 0.0 0.6 1 0.1 0.0 0.6
Oral lichen planus 0 0 0.0 0.4 1 0.1 0.0 0.6
Metabolism and nutrition disorders
Diabetes mellitus 1 0.1 0.0 0.6 0 0 0.0 0.4
Musculoskeletal and connective tissue disorders
Mixed connective tissue disease 0 0 0.0 0.4 1 0.1 0.0 0.6
Polymyalgia rheumatica 2 0.2 0.0 0.7 3 0.3 0.1 0.9
Rheumatoid arthritis 0 0 0.0 0.4 6 0.6 0.2 1.4
Still’s disease adult onset 1 0.1 0.0 0.6 0 0 0.0 0.4
Systemic lupus erythematosus 0 0 0.0 0.4 1 0.1 0.0 0.6
Nervous system disorders
Chronic inflammatory demyelinating polyradiculoneuropathy 0 0 0.0 0.4 1 0.1 0.0 0.6
Guillain-Barré syndrome 1 0.1 0.0 0.6 1 0.1 0.0 0.6
Multiple sclerosis 0 0 0.0 0.4 1 0.1 0.0 0.6
Neuritis cranial 1 0.1 0.0 0.6 0 0 0.0 0.4
Paraneoplastic neurological syndrome 0 0 0.0 0.4 1 0.1 0.0 0.6
Radiculitis brachial 1 0.1 0.0 0.6 0 0 0.0 0.4
Trigeminal nerve paresis 0 0 0.0 0.4 1 0.1 0.0 0.6
Trigeminal neuralgia 1 0.1 0.0 0.6 0 0 0.0 0.4
Renal and urinary disorders
Glomerulonephritis 0 0 0.0 0.4 1 0.1 0.0 0.6
IgA nephropathy 1 0.1 0.0 0.6 0 0 0.0 0.4
Respiratory, thoracic and mediastinal disorders
Idiopathic pulmonary fibrosis 1 0.1 0.0 0.6 0 0 0.0 0.4
Pulmonary fibrosis 0 0 0.0 0.4 1 0.1 0.0 0.6
Skin and subcutaneous tissue disorders
Erythema nodosum 1 0.1 0.0 0.6 0 0 0.0 0.4
Lichen planus 1 0.1 0.0 0.6 2 0.2 0.0 0.8
Psoriasis 1 0.1 0.0 0.6 0 0 0.0 0.4
Vascular disorders
Polyarteritis nodosa 0 0 0.0 0.4 1 0.1 0.0 0.6
Potential immune-mediated diseases (pIMDs) are presented by System Organ Class and Preferred Term, in alphabetical order. RZV = participants receiving the adjuvanted
Recombinant Zoster Vaccine; Placebo = participants receiving placebo; N = number of participants with a pre-existing pIMD at enrolment; n/% = number/percentage of
participants reporting an event in each category; 95% CI = 95% Confidence Interval; LL/UL = Lower Limit/Upper Limit of 95% Confidence Interval.
Participants with pre-existing pIMDs were identified by querying the global medical history of the participants included in the Total Vaccinated Cohort with a customized
MedDRA query for pIMDs [Tavares 2013].
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irrespective of age, gender or race. Similarly, SAEs considered
related to study vaccination by the investigator were balanced
between groups. A descriptive analysis revealed that supraventric-
ular tachycardia was the only SAE by PT with an increased risk in
RZV recipients up to 1Y post-last vaccination. However, given the
high number of comparisons, the probability of obtaining a false
significant increase in the incidence of a particular event is inflated.
The analysis performed considering grouped PTs referring to the
same medical context of supraventricular tachyarrhythmias did
not show any apparent differences between RZV and placebo
recipients. In addition, no biologically plausible mechanism by
which RZV could cause supraventricular tachycardia is known.
The incidence of AEs with a fatal outcome reflected the age of
participants [13,14], and was balanced between RZV and placeborecipients. One fatal AE (neutropenic sepsis) that occurred more
than 3M post-vaccination, was considered related to vaccination
by the study investigator [4]. The neutropenia and neutropenic
sepsis in this participant were likely the result of the induction
chemotherapy for the treatment of AML. Additionally, there were
no clustering of similar events temporally associated with vaccina-
tion. Neutropenic fever and sepsis are common AEs for therapeutic
treatment [15–17].
Although concerns have been raised regarding potential associ-
ations between vaccine adjuvants and the occurrence of pIMDs
[18–20], the association between vaccination and pIMDs has lar-
gely been extrapolated from isolated case reports, and large epi-
demiological studies and pooled analyses only showed such an
association for a very limited number of vaccine and autoimmune
disease combinations [21,22]. The theoretical risk of acquiring
2492 M. López-Fauqued et al. / Vaccine 37 (2019) 2482–2493autoimmune diseases is considered to be driven by chronic
inflammation, antigen mimicry and inflammation of target organs
[23]. However, pre-clinical evidence suggests that RZV is unlikely
to cause long-term inflammation, as the innate immune response
and activity of pro-inflammatory cytokines are transient [24].
Nonetheless, in the ZOE-50/70 studies, pIMDs were monitored
through standard data collection methods and disease-specific
standard questionnaires for the collection of the pIMD safety data
[25]. In eligible participants with pre-existing pIMDs at study
entry, exacerbations as well as new onset of other pIMDs were
recorded during the entire study period. The analyses of the
pooled study population presented here show no evidence for a
statistical imbalance between RZV and placebo recipients. Overall,
the most frequently reported pIMDs were those with the greatest
prevalence in this age group [26–29]. The occurrence of new onset
pIMDs was similar between groups, irrespective of time interval
assessed, participant age, gender, or race. Additionally, in partici-
pants with pre-existing pIMDs, the occurrences of a possible exac-
erbation or a new onset of a different pIMD were also balanced
between groups. Overall, these data do not show an increased risk
of developing a new pIMD or exacerbating an underlying pIMD in
RZV recipients 50 YOA.
The results of these pooled analyses need to be considered in
the context of study strengths and weaknesses. The ZOE-50/70
clinical trials included a large and global population of relevant
age, predominantly of Caucasian and Asian ancestries. The statisti-
cal power of pre-licensure clinical trials to detect very rare events
is limited due to the sample size. Since incidence rates of some
medical conditions, such as certain pIMDs and allergic reactions
vary roughly from 1 to 20 per 100,000 person-years in the general
population, these AEs will require post-licensure safety monitor-
ing, during which a larger population will be vaccinated. In addi-
tion, some populations were excluded per protocol from the
pivotal studies (e.g. patients with certain underlying diseases trea-
ted with high dose steroids or immune-modulators).
The pooled analyses of the phase 3 ZOE-50/70 clinical trials did
not identify any safety concerns, and, along with the high vaccine
efficacy demonstrated in these trials, these results support the
favorable benefit-risk profile of RZV in all age-groups studied.5. Potential conflicts of interest
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